Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility

Journal of Virology

Volumn 83, Issue 15, 2009, Pages 7434-7439

  Puertas, Maria Carmen ^a   Buzón, Maria Jose ^a   Artese, Anna ^b   Alcaro, Stefano ^b   Menendez Arias, Luis ^c   Perno, Carlo Federico ^d   Clotet, Bonaventura ^a   Ceccherini Silberstein, Francesca ^d   Martinez Picado, Javier ^a,e  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; GENETIC POLYMORPHISM; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; VIROGENESIS; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LEUCINE; MUTATION; POLYMORPHISM, GENETIC; VIRUS REPLICATION; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 67650924884     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00487-09     Document Type: Article

References (34)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Alcaro, S., F. Gasparrini, O. Incani, S. Mecucci, D. Misiti, M. Pierini, and C. Villani. 2000. A quasi-flexible automatic docking processing for studying stereoselective recognition mechanisms. Part I. Protocol Validation. J. Comp. Chem. 21:515-530.
3. Ceccherini-Silberstein, F., A. Cozzi-Lepri, L. Ruiz, A. Mocroft, A. N. Phillips, C. H. Olsen, J. M. Gatell, H. F. Gunthard, P. Reiss, C. F. Perno, B. Clotet, and J. D. Lundgren. 2007. Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients. J. Infect. Dis. 196:1180-1190.
4. Ceccherini-Silberstein, F., F. Gago, M. Santoro, C. Gori, V. Svicher, F. Rodriguez-Barrios, R. d'Arrigo, M. Ciccozzi, A. Bertoli, A. d'Arminio monforte, J. Balzarini, A. Antinori, and C. F. Perno. 2005. High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. J. Virol. 79:10718-10729.
5. Cong, M. E., W. Heneine, and J. G. Garcia-Lerma. 2007. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J. Virol. 81:3037-3041.
6. Cozzi-Lepri, A., L. Ruiz, C. Loveday, A. N. Phillips, B. Clotet, P. Reiss, B. Ledergerber, C. Holkmann, S. Staszewski, and J. D. Lundgren. 2005. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir. Ther. 10:791-802.
7. De Luca, A., S. Di Giambenedetto, L. Romano, A. Gonnelli, P. Corsi, M. Baldari, M. Di Pietro, S. Menzo, D. Francisci, P. Almi, and M. Zazzi. 2006. Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy. J. Infect. Dis. 193:1219-1222.
8. Flandre, P., D. Descamps, V. Joly, V. Meiffredy, C. Tamalet, J. Izopet, and F. Brun-Vezinet. 2004. A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients. J. Infect. Dis. 189:862-870.
9. Gibbs, J. S., D. A. Regier, and R. C. Desrosiers. 1994. Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes. AIDS Res. Hum. Retrovir. 10:343-350.
10. Gonzales, M. J., T. D. Wu, J. Taylor, I. Belitskaya, R. Kantor, D. Israelski, S. Chou, A. R. Zolopa, W. J. Fessel, and R. W. Shafer. 2003. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 17:791-799.
11. Halgren, T. A. 1996. Merck molecular force field. I, II, III, IV, and V. J. Comput. Chem. 17:490-641.
12. Hanna, G. J., V. A. Johnson, D. R. Kuritzkes, D. D. Richman, A. J. Brown, A. V. Savara, J. D. Hazelwood, and R. T. D'Aquila. 2000. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J. Infect. Dis. 181:904-911.
13. Harrigan, P. R., S. Bloor, and B. A. Larder. 1998. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J. Virol. 72:3773-3778.
14. Harrigan, P. R., I. Kinghorn, S. Bloor, S. D. Kemp, I. Najera, A. Kohli, and B. A. Larder. 1996. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J. Virol. 70:5930-5934.
15. Japour, A. J., S. Welles, R. T. D'Aquila, V. A. Johnson, D. D. Richman, R. W. Coombs, P. S. Reichelderfer, J. O. Kahn, C. S. Crumpacker, D. R. Kuritzkes, et al. 1995. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J. Infect. Dis. 171:1172-1179.
16. John, M., C. B. Moore, I. R. James, and S. A. Mallal. 2005. Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1. Antivir. Ther. 10:551-555.
17. Korber, B. T., B. T. Foley, K. L. Kuiken, S. K. Pillai, and J. G. Sodroski. 1998. Numbering positions in HIV relative to HXB2CG, p. 102-111. In C. Kuiken, B. Foley, B. Hahn, P. Marx, F. McCutchan, J. Mellors, S. Wolinsky, and B. Korber (ed.), HIV sequence compendium 1998. Theoretical Biology and Biophysics Group, Los Alamos, NM.
18. Li, M., F. Gao, J. R. Mascola, L. Stamatatos, V. R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K. M. Greene, M. Bilska, D. L. Kothe, J. F. Salazar-Gonzalez, X. Wei, J. M. Decker, B. H. Hahn, and D. C. Montefiori. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125.
19. Marcelin, A. G., C. Delaugerre, M. Wirden, P. Viegas, A. Simon, C. Katlama, and V. Calvez. 2004. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J. Med. Virol. 72:162-165.
20. Martinez-Picado, J., and M. A. Martinez. 2008. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res. 134:104-123.
21. Martinez-Picado, J., T. Wrin, S. D. Frost, B. Clotet, L. Ruiz, A. J. Brown, C. J. Petropoulos, and N. T. Parkin. 2005. Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1. J. Virol. 79:5907-5913.
22. Meyer, P. R., S. E. Matsuura, A. G. So, and W. A. Scott. 1998. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. USA 95:13471- 13476.
23. Miller, M. D., N. Margot, B. Lu, L. Zhong, S. S. Chen, A. Cheng, and M. Wulfsohn. 2004. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral- experienced patients. J. Infect. Dis. 189:837-846.
24. Mohamadi, F., N. G. J. Richards, W. C. Guida, R. Liskamp, M. Lipton, C. Caufield, G. Chang, T. Hendrickson, and W. C. Still. 1990. MacroModel: an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 11:440-467.
25. Ntemgwa, M., M. A. Wainberg, M. Oliveira, D. Moisi, R. Lalonde, V. Micheli, and B. G. Brenner. 2007. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob. Agents Chemother. 51:3861-3869.
26. Rhee, S. Y., T. Liu, J. Ravela, M. J. Gonzales, and R. W. Shafer. 2004. Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrob. Agents Chemother. 48:3122-3126.
27. Sarafianos, S. G., A. D. Clark, Jr., K. Das, S. Tuske, J. J. Birktoft, P. Ilankumaran, A. R. Ramesha, J. M. Sayer, D. M. Jerina, P. L. Boyer, S. H. Hughes, and E. Arnold. 2002. Structures of HIV-1 reverse transcriptase with pre- and posttranslocation AZTMP-terminated DNA. EMBO J. 21:6614-6624.
28. Sturmer, M., S. Staszewski, H. W. Doerr, B. Larder, S. Bloor, and K. Hertogs. 2003. Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214. Antimicrob. Agents Chemother. 47:54-61.
29. Svicher, V., T. Sing, M. M. Santoro, F. Forbici, F. Rodriguez-Barrios, A. Bertoli, N. Beerenwinkel, M. C. Bellocchi, F. Gago, A. d'Arminio Monforte, A. Antinori, T. Lengauer, F. Ceccherini-Silberstein, and C. F. Perno. 2006. Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J. Virol. 80:7186-7198.
30. Villena, C., J. G. Prado, M. C. Puertas, M. A. Martinez, B. Clotet, L. Ruiz, N. T. Parkin, L. Menendez-Arias, and J. Martinez-Picado. 2007. Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region. J. Virol. 81:4713-4721.
31. Wallace, A. C., R. A. Laskowski, and J. M. Thornton. 1995. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8:127-134.
32. Wolf, K., H. Walter, N. Beerenwinkel, W. Keulen, R. Kaiser, D. Hoffmann, T. Lengauer, J. Selbig, A. M. Vandamme, K. Korn, and B. Schmidt. 2003. Tenofovir resistance and resensitization. Antimicrob. Agents Chemother. 47:3478-3484.
33. Yahi, N., C. Tamalet, C. Tourres, N. Tivoli, F. Ariasi, F. Volot, J. A. Gastaut, H. Gallais, J. Moreau, and J. Fantini. 1999. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. J. Clin. Microbiol. 37:4099-4106.
34. Yahi, N., C. Tamalet, C. Tourres, N. Tivoli, and J. Fantini. 2000. Mutation L210W of HIV-1 reverse transcriptase in patients receiving combination therapy. Incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase. J. Biomed. Sci. 7:507-513.